Omnicell Com Stock Price, News & Analysis

Omnicell, a leader in medication management, has entered a 10-year agreement with UMC Health System in Lubbock, Texas, to implement its cloud-based solutions for pharmacy automation and patient engagement. This partnership aims to enhance operational efficiency and patient safety through advanced pharmacy technology.

With UMC's significant demand increase and high uninsured rates in Texas, the solutions are expected to improve health outcomes in underserved communities.

Omnicell's Autonomous Pharmacy vision will drive performance and allow clinicians to focus more on patient care.

Omnicell, Inc. (NASDAQ:OMCL) reported a robust performance in 2021, achieving total revenues of $1.132 billion, a 27% increase from the previous year. Fourth quarter revenues reached $311 million, marking a 25% year-over-year growth. The company ended 2021 with a product backlog of $1.254 billion and completed acquisitions to expand its service offerings. For 2022, Omnicell expects revenues between $1.385 billion and $1.410 billion, with guidance aiming for non-GAAP earnings of $3.75 to $3.95 per share.

Omnicell, Inc. (NASDAQ:OMCL) will release its financial results for Q4 and full-year 2021 on February 14, 2022, after market close. A conference call and webcast to discuss these results will follow at 1:30 p.m. PT the same day. Interested parties can participate by calling (888) 550-5424 in the U.S. or (646) 960-0819 internationally. Omnicell focuses on improving pharmacy care delivery through automation and technology, with over 7,000 facilities utilizing its solutions globally.

Omnicell has acquired MarkeTouch Media for $82 million, enhancing its EnlivenHealth division's reach in the retail pharmacy market. The acquisition aims to leverage MarkeTouch's mobile and web-based patient engagement solutions, potentially expanding into specialty pharmacy and pharmacy benefits management sectors. MarkeTouch recorded approximately $14 million in revenue for the year ending October 31, 2021. This move is expected to boost Omnicell's non-GAAP EBITDA and earnings per share immediately.

Omnicell has acquired ReCept Holdings for $100 million, enhancing its Advanced Services portfolio in specialty pharmacy management. The acquisition is projected to boost Omnicell's non-GAAP EBITDA starting Q1 2023, aligning with its strategy to address the complex specialty pharmacy market. ReCept reported annual recurring revenue of $24 million as of September 30, 2021. This addition allows Omnicell to optimize specialty pharmacy programs and improve patient care, further solidifying its position in medication management solutions.

Omnicell announced its strategic acquisition of ReCept Holdings for $100 million, aiming to enhance its Advanced Services portfolio. This acquisition responds to the growing need for effective management of complex medications, which represent over 50% of the U.S. drug spending. ReCept's capabilities in specialty pharmacy management will support Omnicell's vision of an Autonomous Pharmacy. This transaction is expected to close by year-end 2022 and will be accretive to Omnicell's non-GAAP EBITDA in Q1 2023.

Omnicell, Inc. (NASDAQ: OMCL) announced its participation in two upcoming investor conferences. Randall Lipps, Chairman and CEO, along with Scott Seidelmann, Executive VP, will present at the Piper Sandler 33rd Annual Virtual Healthcare Conference on December 1, 2021, at 9:00 am ET. Additionally, Peter Kuipers, Executive VP and CFO, will appear at the 2021 Stephens Annual Investment Conference on December 3, 2021, at 10:00 am CT in Nashville, TN. Webcasts of both presentations will be accessible on the Omnicell website.

Omnicell, Inc. (NASDAQ:OMCL) is collaborating with Fresenius Kabi to enhance pharmacy technology in U.S. hospitals. Their partnership introduces the Controlled Substance Dispenser (CSD), targeting improved management of controlled substances and increased efficiency in medication dispensing. This innovation aims to mitigate the significant loss of medication—over 148 million doses in 2019—which affects patient and workforce safety. The newly designed cassettes for Omnicell's CSD support Fresenius Kabi's MicroVault prefilled syringes, streamlining processes for healthcare providers.

Omnicell (NASDAQ: OMCL) announced the Tucson VA Medical Center as the first Veterans Affairs facility to implement its Central Pharmacy Dispensing Service (CPDS). This initiative aims to enhance patient safety, increase operational efficiency, and optimize inventory management in pharmacy operations. The partnership highlights Omnicell's commitment to transforming pharmacy care delivery through automation and technology, supporting the Veterans Health Administration's mission to serve 9 million veterans annually.